Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®

Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus

This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.

Inclusion Criteria:

• Type 2 diabetes
• HbA1c greater than 7.0% and/or hypoglycaemia
• variable FBG and/or weight increase
• the selection of the subjects will be at the discretion of the participating physician

Exclusion Criteria:

• non-type 2 diabetes
• current treatment with Levemir® or Insulatard®
• hypersensitivity to Levemir® or Insulatard® or to any of the excipients
• women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months